Literature DB >> 25633172

Therapeutic implications of orally delivered immunomodulatory oligonucleotides.

Dennis M Klinman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25633172      PMCID： PMC4445629          DOI： 10.1038/mt.2014.251

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

1.  Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.

Authors:  M J McCluskie; H L Davis
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

2.  Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation.

Authors:  Ihsan Gursel; Mayda Gursel; Hiroshi Yamada; Ken J Ishii; Fumihiko Takeshita; Dennis M Klinman
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

Review 3.  Immunotherapeutic uses of CpG oligodeoxynucleotides.

Authors:  Dennis M Klinman
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

4.  CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation.

Authors:  P Lenert; L Stunz; A K YI; A M Krieg; R F Ashman
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-08

Review 5.  Therapeutic potential of Toll-like receptor 9 activation.

Authors:  Arthur M Krieg
Journal:  Nat Rev Drug Discov       Date:  2006-06       Impact factor: 84.694

6.  Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice.

Authors:  Yeqin Wang; Yoshinari Yamamoto; Suguru Shigemori; Takafumi Watanabe; Kazushi Oshiro; Xinyu Wang; Pengfei Wang; Takashi Sato; Shinichi Yonekura; Sachi Tanaka; Haruki Kitazawa; Takeshi Shimosato
Journal:  Mol Ther       Date:  2014-12-15       Impact factor: 11.454

Review 7.  The microbiome and regulation of mucosal immunity.

Authors:  Andrew J McDermott; Gary B Huffnagle
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

Review 8.  Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides.

Authors:  Dennis M Klinman; Debbie Tross; Sven Klaschik; Hidekazu Shirota; Takeshi Sato
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

Review 9.  Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

Authors:  Julia Scheiermann; Dennis M Klinman
Journal:  Vaccine       Date:  2014-06-24       Impact factor: 3.641

10.  Class I/II hybrid inhibitory oligodeoxynucleotide exerts Th1 and Th2 double immunosuppression.

Authors:  Yusuke Ito; Suguru Shigemori; Takashi Sato; Tomoyuki Shimazu; Konomi Hatano; Hajime Otani; Haruki Kitazawa; Takeshi Shimosato
Journal:  FEBS Open Bio       Date:  2012-11-12       Impact factor: 2.693
View more
  2 in total

1.  Synthetic Oligodeoxynucleotides Containing Multiple Telemeric TTAGGG Motifs Suppress Inflammasome Activity in Macrophages Subjected to Oxygen and Glucose Deprivation and Reduce Ischemic Brain Injury in Stroke-Prone Spontaneously Hypertensive Rats.

Authors:  Jing Zhao; Yongshan Mou; Joshua D Bernstock; Dace Klimanis; Sixian Wang; Maria Spatz; Dragan Maric; Kory Johnson; Dennis M Klinman; Xiaohong Li; Xinhui Li; John M Hallenbeck
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

2.  Free Feeding of CpG-Oligodeoxynucleotide Particles Prophylactically Attenuates Allergic Airway Inflammation and Hyperresponsiveness in Mice.

Authors:  Takuma Okajima; Suguru Shigemori; Fu Namai; Tasuku Ogita; Takashi Sato; Takeshi Shimosato
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.